Drug efflux by Breast Cancer Resistance Protein (BCRP) is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924

BACKGROUND: Preclinical investigations have identified insulin-like growth factor (IGF) signaling as a key mechanism for cancer growth and resistance to clinically useful therapies in multiple tumor types, including breast cancer. Thus, agents targeting and blocking IGF signaling have promise in the...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Hou, Xiaonan, Huang, Fei, Carboni, Joan M., Flatten, Karen, Asmann, Yan W., Eyck, Cynthia Ten, Nakanishi, Takeo, Tibodeau, Jennifer D., Ross, Douglas D., Gottardis, Marco M., Erlichman, Charles, Kaufmann, Scott H., Haluska, Paul
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2011
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3057506/
https://ncbi.nlm.nih.gov/pubmed/21220496
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-10-0438
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia